Active enhancement methods for intra- and transdermal drug delivery: A review;Aktivne metode pospeševanja dermalnega in transdermalnega vnosa zdravilnih učinkovin

Zdravniski Vestnik

Volumn 82, Issue 5, 2013, Pages 339-356

  Zorec, Barbara ^a   Préat, Véronique ^b   Miklavčič, Damijan ^a   Pavšelj, Nataša ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Electroporation; Iontophoresis; Microneedles; Penetration enhancers; Stratum corneum

Indexed keywords

DRUG; FENTANYL; LIDOCAINE; LIPOSOME; PENETRATION ENHANCING AGENT; PRODRUG;

ACTIVE TRANSPORT; DERMIS; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG METABOLISM; DRUG PENETRATION; DRUG STRUCTURE; ELECTROPORATION; EPIDERMIS; FIRST PASS EFFECT; HUMAN; HYDROPHILICITY; INTERMETHOD COMPARISON; IONIZATION; IONTOPHORESIS; LASER; LIPOPHILICITY; MICRONEEDLE; MOLECULAR SIZE; MOLECULAR WEIGHT; PAIN; PASSIVE TRANSPORT; PATIENT COMPLIANCE; PHYSICAL CHEMISTRY; PROCESS OPTIMIZATION; RADIOFREQUENCY ABLATION; RADIOFREQUENCY MICROABLATION; REVIEW; SKIN APPENDAGE; SKIN FUNCTION; SKIN PENETRATION; SKIN PERMEABILITY; SKIN STRUCTURE; SONOPHORESIS; STRATUM CORNEUM; SUBCUTANEOUS TISSUE; TRANSCYTOSIS; TRANSDERMAL PATCH; ULTRASOUND;

EID: 84878145485     PISSN: 13180347     EISSN: 15810224     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. Peter M. E. Epidermal barrier function: intercellular lamellar lipid structures, origin, composition and metabolism. Journal of Controlled Release. 1991; 15: 199-208.
2. Williams AC. Transdermal and Topical Drug Delivery: From Theory to Clinical Practice. 1st ed. Pharmaceutical Press; 2004.
3. Naik, Kalia, Guy. Transdermal drug delivery: overcoming the skin's barrier function. Pharm. Sci. Technol. Today. 2000; 3: 318-26.
4. Gašperlin M. Transdermal drug delivery. Pharmaceutical journal of Slovenia. 2006; 100-6.
5. Prausnitz MR, Mitragotri S, Langer R. Current status and future potential of transdermal drug delivery. Nat Rev Drug Discov. 2004; 3: 115-24.
6. Bos JD, Meinardi MMHM. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Experimental Dermatology. 2000; 9: 165-9.
7. Shore PA, Brodie BB, Hogben CAM. The gastric secretion of drugs: a pH patrition hypotesis. Journal of Pharmacology and Experimental Therapeutics. 1957; 119: 361-369.
8. Prausnitz MR. Reversible skin permeabilization for transdermal delivery of macromolecules. Critical reviews in therapeutic drug carrier systems. 1995; 14: 455.
9. Barry BW. Is transdermal drug delivery research still important today? Drug Discovery Today. 2001; 6: 967-71.
10. Thomas BJ, Finnin BC. The transdermal revolution. Drug Discovery Today. 2004;: 697-703.
11. Asbill CS, Michniak BB. Percutaneous penetration enhancers: local versus transdermal activity. Pharmaceutical Science & Technology Today. 2000; 3: 36-41.
12. Williams AC, Barry BW. Penetration enhancers. Adv. Drug Deliv. Rev. 2004; 56: 603-18.
13. Pathan IB, Setty CM. Chemical Penetration Enhancers for Transdermal Drug Delivery Systems. Tropical Journal of Pharmaceutical Research 2009; 8:173 [cited 2012 Feb 9]. Dosegljivo na: http://www.ajol.info/index.php/tjpr/article/ view/44527
14. Guy RH. Transdermal Drug Delivery. In: Schäfer-Korting M, ed. Drug Delivery Berlin: Springer. 2010. p. 399-410 [cited 2012 Feb 9]. Dosegljivo na: http://www.springerlink.com/content/ l6524454476502mr/.
15. Kristl J, Teskač K, Grabnar PA. Current View on Nanosized Solid Lipid Carriers for Drug Delivery to the Skin. Journal of Biomedical Nanotechnology. 2010; 6: 529-42.
16. Brown MB, Martin GP, Jones SA, Akomeah FK. Dermal and transdermal drug delivery systems: current and future prospects. Drug Deliv. 2006; 13: 175-87.
17. Benson HAE, Namjoshi S. Proteins and peptides: strategies for delivery to and across the skin. J Pharm Sci. 2008; 97: 3591-610.
18. Pikal MJ. The role of electroosmotic flow in transdermal iontophoresis. Adv. Drug Deliv. Rev. 2001; 46: 281-305.
19. Wang Y, Thakur R, Fan Q, Michniak B. Transdermal iontophoresis: combination strategies to im prove transdermal iontophoretic drug delivery. European Journal of Pharmaceutics and Biopharmaceutics. 2005; 60: 179-91.
20. Zempsky WT, Sullivan J, Paulson DM, Hoath SB. Evaluation of a low-dose lidocaine iontophoresis system for topical anesthesia in adults and children: a randomized, controlled trial. Clin Ther. 2004; 26: 1110-9.
21. Bertolucci LE. Introduction of Antiinflammatory Drugs by lontophoresis: Double Blind Study. J Orthop Sports Phys Ther. 1982; 4: 103-8.
22. Harris PR. lontophoresis: Clinical Research in Musculoskeletal lnf lammatory Conditions. J Orthop Sports Phys Ther. 1982; 4: 109-12.
23. Beauchamp M, Lands LC. Sweat-testing: a review of current technical requirements. Pediatr. Pulmonol. 2005; 39: 507-11.
24. Kreyden OP. Iontophoresis for palmoplantar hyperhidrosis. J Cosmet Dermatol. 2004; 3: 211-4.
25. Mayes S, Ferrone M. Fentanyl HCl patient-controlled iontophoretic transdermal system for the management of acute postoperative pain. Ann Pharmacother. 2006; 40: 2178-86.
26. Tamada JA, Garg S, Jovanovic L, Pitzer KR, Fermi S, Potts RO. Noninvasive glucose monitoring: comprehensive clinical results. Cygnus Research Team. JAMA. 1999; 282: 1839-44.
27. Sieg A, Guy RH, Delgado-Charro MB. Noninvasive Glucose Monitoring by Reverse Iontophoresis in Vivo: Application of the Internal Standard Concept. Clinical Chemistry. 2004; 50: 1383-90.
28. Potts R. Frequent and automatic glucose monitoring using the GlucoWatch (R) Biographer. Abstr. Pap. Am. Chem. Soc. 2002; 224:U114-U114.
29. Banga AK, Bose S, Ghosh TK. Iontophoresis and electroporation: comparisons and contrasts. Int J Pharm. 1999; 179: 1-19.
30. Hu L, Batheja P, Meidan V, Michniak-Kohn BB. CHAPTER 4-Iontophoretic Transdermal Drug Delivery. Handbook of Non-Invasive Drug Delivery Systems [Internet]. Boston: William Andrew Publishing; 2010. p. 95-118. [cited 2012 Feb 9]. Available from: http://www.sciencedirect.com/ science/article/pii/B9780815520252100046
31. Yoshida NH, Roberts MS. Solute molecular size and transdermal iontophoresis across excised human skin. Journal of Controlled Release. 1993; 25: 177-95.
32. Denet A-R, Vanbever R, Préat V. Skin electroporation for transdermal and topical delivery. Adv. Drug Deliv. Rev. 2004; 56: 659-74.
33. Kotnik T, Pucihar G, Miklavčič D. Induced Transmembrane Voltage and Its Correlation with Electroporation-Mediated Molecular Transport. Journal of Membrane Biology. 2010; 236: 3-13.
34. Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008 Nov; 26: 1261-8.
35. Pliquett U, Weaver JC. Feasibility of an Electrode--Reservoir Device for Transdermal Drug Delivery by Noninvasive Skin Electroporation. IEEE Transactions on Biomedical Engineering. 2007; 54: 536-8.
36. Pavselj N, Préat V, Miklavcic D. A numerical model of skin electropermeabilization based on in vivo experiments. Ann Biomed Eng. 2007; 35: 2138-44.
37. Pavselj N, Miklavcic D. A Numerical Model of Permeabilized Skin With Local Transport Regions. IEEE Transactions on Biomedical Engineering 2008; 55: 1927-30.
38. Vanbever R, Le Boulenge E, Préat V. Transdermal Delivery of Fentanyl by Electroporation I. Influence of electrical factors. Pharmaceutical Research 1996: 559-65.
39. Regnier V, De Morre N, Jadoul A, Préat V. Mechanisms of a phosphorothioate oligonucleotide delivery by skin electroporation. International Journal of Pharmaceutics. 1999; 184: 147-56.
40. Dujardin N, Van Der Smissen P, Préat V. Topical Gene Transfer into Rat Skin Using Electroporation. Pharmaceutical Research. 2001: 61-6.
41. Pavselj N, Préat V. DNA electrotransfer into the skin using a combination of one high-and one low-voltage pulse. J Control Release. 2005; 106: 407-15.
42. Lavon I, Kost J. Ultrasound and transdermal drug delivery. Drug Discov Today 2004; 9: 670-6.
43. Smith NB. Perspectives on transdermal ultrasound mediated drug delivery. Int J Nanomedicine. 2007; 2: 585-94.
44. Menon GK, Kollias N, Doukas AG. Ultrastructural evidence of stratum corneum permeabilization induced by photomechanical waves. J. Invest. Dermatol. 2003; 121: 104-9.
45. Tang H, Wang CCJ, Blankschtein D, Langer R. An investigation of the role of cavitation in low--frequency ultrasound-mediated transdermal drug transport. Pharm. Res. 2002; 19: 1160-9.
46. Swain S, Beg S, Singh A, Patro CN, Rao MEB. Advanced techniques for penetration enhancement in transdermal drug delivery system. Curr Drug Deliv 2011; 8: 456-73.
47. Mitragotri S, Kost J. Low-frequency sonophoresis: a review. Adv. Drug Deliv Rev 2004; 56: 589-601.
48. Mitragotri S, Blankschtein D, Langer R. Ultrasound-mediated transdermal protein delivery. Science 1995; 269: 850-853.
49. Meidan V.M., Docker M.F., Walmsley A.D., Irwin W.J. Phonophoresis of hydrocortisone with enhancers: an acoustically defined model. International Journal of Pharmaceutics 1998; 170: 157-68.
50. Escobar-Chavez JJ, Bonilla-Martínez D, Villegas--González MA, Rodríguez-Cruz IM, Domínguez-Delgado CL. The Use of Sonophoresis in the Administration of Drugs Throughout the Skin. Journal of Pharmacy & Pharmaceutical Sciences 2009; 12: 88-115.
51. Cabak A, Maczewska M, Lyp M, Dobosz J, Gasiorowska U. The effectiveness of phonophoresis with ketoprofen in the treatment of epicondylopathy. Ortop Traumatol Rehabil 2005; 7: 660-5.
52. Rosim GC, Barbieri CH, Lanças FM, Mazzer N. Diclofenac phonophoresis in human volunteers. Ultrasound Med Biol 2005; 31: 337-43.
53. Serikov NP. Efficacy of ibuprofen (nurofen gel) ultraphonophoresis for pain relief in osteoarthrosis. Ter Arkh. 2007; 79: 79-81.
54. Kim T-Y, Jung D-I, Kim Y-I, Yang J-H, Shin S-C. Anesthetic effects of lidocaine hydrochloride gel using low frequency ultrasound of 0.5 MHz. J Pharm Pharm Sci 2007; 10: 1-8.
55. Ueda H, Sugibayashi K, Morimoto Y. Skin penetration-enhancing effect of drugs by phonophoresis. Journal of Controlled Release 1995; 37: 291-7.
56. Izzo F, Thomas R, Delrio P, Rinaldo M, Vallone P, DeChiara A, et al. Radiofrequency ablation in patients with primary breast carcinoma. Cancer 2001; 92: 2036-44.
57. Nahum Goldberg S, Kamel IR, Kruskal JB, Reynolds K, Monsky WL, Stuart KE, et al. Radiofrequency Ablation of Hepatic Tumors: Increased Tumor Destruction with Adjuvant Liposomal Doxorubicin Therapy. AJR 2002; 179: 93-101.
58. Sintov AC, Krymberk I, Daniel D, Hannan T, Sohn Z, Levin G. Radiofrequency-driven skin microchanneling as a new way for electrically assisted transdermal delivery of hydrophilic drugs. Journal of Controlled Release 2003; 89: 311-20.
59. Levin G, Gershomowitz A, Sacks H, Stern M, Sherman A, Rudaev S, et al. Transdermal Delivery of Human Growth Hormone Through RF-Microchannels. Pharmaceutical Research 2005; 550-5.
60. Birchall J, Coulman S, Anstey A, Gateley C, Sweetland H, Gershonowitz A, et al. Cutaneous gene expression of plasmid DNA in excised human skin following delivery via microchannels created by radio frequency ablation. Int J Pharm 2006; 312: 15-23.
61. Gómez C, Costela A, García-Moreno I, Llanes F, Teijón JM, Blanco D. Laser treatments on skin enhancing and controlling transdermal delivery of 5-fluorouracil. Lasers Surg Med 2008; 40: 6-12.
62. Fang J-Y, Lee W-R, Shen S-C, Wang H-Y, Fang C-L, Hu C-H. Transdermal delivery of macromolecules by erbium:YAG laser. Journal of Controlled Release 2004; 100: 75-85.
63. Jacques SL, McAuliffe DJ, Blank IH, Parrish JA. Controlled Removal of Human Stratum Corneum by Pulsed Laser. J Investig Dermatol 1987; 88: 88-93.
64. Oni G, Brown SA, Kenkel JM. Can fractional lasers enhance transdermal absorption of topical lidocaine in an in vivo animal model? Lasers Surg Med 2012; 44: 168-74.
65. Lee S, McAuliffe DJ, Flotte TJ, Kollias N, Doukas AG. Photomechanical transdermal delivery: the effect of laser confinement. Lasers Surg Med 2001; 28: 344-7.
66. Lee S, McAuliffe DJ, Flotte TJ, Kollias N, Doukas AG. Photomechanical Transcutaneous Delivery of Macromolecules
67. Prausnitz MR. Microneedles for transdermal drug delivery. Advanced Drug Delivery Reviews 2004; 56: 581-7.
68. McAllister DV, Wang PM, Davis SP, Park J-H, Canatella PJ, Allen MG, et al. Microfabricated needles for transdermal delivery of macromolecules and nanoparticles: fabrication methods and transport studies. Proc Natl Inst Sci 2003; 100: 13755-60.
69. van der Maaden K, Jiskoot W, Bouwstra J. Microneedle technologies for (trans)dermal drug and vaccine delivery. Journal of Controlled Release 2012; 161: 645-55.
70. Wermeling DP, Banks SL, Hudson DA, Gill HS, Gupta J, Prausnitz MR, et al. Microneedles permit transdermal delivery of a skin-impermeant me-dication to humans. Proceedings of the National Academy of Science 2008; 105: 2058-2063.
71. Daugimont L, Baron N, Vandermeulen G, Pavselj N, Miklavcic D, Jullien M-C, et al. Hollow microneedle arrays for intradermal drug delivery and DNA electroporation. J Membr Biol 2010; 236: 117-25.
72. Ito Y, Yoshimitsu J-I, Shiroyama K, Sugioka N, Takada K. Self-dissolving microneedles for the percutaneous absorption of EPO in mice. Journal of Drug Targeting 2006; 14: 255-61.
73. Lee JW, Park J-H, Prausnitz MR. Dissolving Microneedles for Transdermal Drug Delivery. Biomaterials 2008; 29: 2113-24.
74. Martanto W, Davis SP, Holiday NR, Wang J, Gill HS, Prausnitz MR. Transdermal delivery of insulin using microneedles in vivo. Pharm Res. 2004; 2: 947-52.
75. Ito Y, Hagiwara E, Saeki A, Sugioka N, Takada K. Feasibility of microneedles for percutaneous absorption of insulin. Eur J Pharm Sci 2006; 29: 82-8.
76. Mikszta JA, Alarcon JB, Brittingham JM, Sutter DE, Pettis RJ, Harvey NG. Improved genetic immunization via micromechanical disruption of skin-barrier function and targeted epidermal delivery. Nat Med 2002; 8: 415-9.
77. Matriano JA, Cormier M, Johnson J, Young WA, Buttery M, Nyam K, et al. Macroflux microprojection array patch technology: a new and efficient approach for intracutaneous immunization. Pharm. Res 2002; 19: 63-70.
78. Widera G, Johnson J, Kim L, Libiran L, Nyam K, Daddona PE, et al. Effect of delivery parameters on immunization to ovalbumin following intracutaneous administration by a coated microneedle array patch system. Vaccine 2006; 24: 1653-64.
79. Banga AK. Transdermal and Intradermal Delivery of Therapeutic Agents: Application of Physical Technologies. Taylor and Francis Group; 2011.
80. Brown MB, Traynor MJ, Martin GP, Akomeah FK. Transdermal drug delivery systems: skin perturbation devices. Methods Mol Biol 2008; 437: 119-39.
81. Pliquett U, Vaughan Z, Weaver J. Apparatus and method for electroporation of tissue. [cited 2012 Feb 17]. Dosegljivo na: http://www.google.si/patents/ US5983131
82. Zhang L, Hofmann GA, Rabussay D. Patent US6266560-Electrically assisted transdermal method and apparatus for the treatment of erectile dysfunction. [cited 2012 Feb 17]. Dosegljivo na: http://www.google.com/patents/US6266560
83. Wong T-W, Chen C-H, Huang C-C, Lin C-D, Hui S-W. Painless electroporation with a new needle--free microelectrode array to enhance transdermal drug delivery. Journal of Controlled Release 2006 Feb; 110: 557-65.